Oncolytic virotherapy has historically been conceived primarily as a mechanism for selective tumour cell lysis. The Perspective reframes this field by emphasizing that modern oncolytic virotherapy functions as a platform for intratumoural immune reprogramming. The authors contend that the commonly used “cold‑to‑hot” paradigm captures only part of the potential of next‑generation oncolytic viruses (OVs). Rather than acting solely to increase tumour inflammation, engineered OVs can deliver coordinated antigen exposure and innate immune adjuvancy to ignite systemic antitumour immunity.
A central point made is that both immune checkpoint inhibitors (ICIs) and early‑generation OVs share a dependence on pre‑existing tumour‑specific T cells (TSTs). This reliance creates an immunological ceiling: agents that primarily unblock or expand existing TSTs are constrained when de novo generation of TSTs is limited. The Perspective highlights that overcoming this ceiling requires therapeutic approaches that can prime new, patient‑specific T cell responses against the tumour proteome rather than relying mainly on previously primed clonotypes.
The first pillar presented is intratumoural vaccination. According to the authors, intratumoural infection by payload‑engineered OVs triggers immunogenic cell death, releasing a broad set of tumour antigens in the context of pathogen‑associated and/or damage‑associated molecular pattern signals. This antigen‑agnostic, in situ vaccination process can prime T cells against patient‑specific neoantigens and, in early clinical observations, has been associated with T cell clonotype broadening, abscopal tumour regressions and survival benefit in some patients who previously failed ICI therapy. The Perspective frames intratumoural vaccination as the immunological ignition step necessary to expand the pool of functional TSTs.
The second pillar focuses on payload engineering to optimize immune priming. Next‑generation OVs can be designed to carry transgenes or molecular payloads that enhance antigen presentation and innate immune activation, thereby hyperactivating antigen‑presenting cells in the tumour microenvironment. The authors assert that such payloads make the intratumoural vaccine signal stronger and more durable, increasing the probability of effective T cell priming against a broad repertoire of tumour antigens without requiring prior antigen knowledge.
The third development pillar addresses clinical trial design and response assessment. Because OV‑mediated antitumour effects can be delayed and can manifest as systemic (abscopal) responses after local administration, conventional response criteria and early on‑treatment endpoints may underestimate benefit. The Perspective recommends revising efficacy evaluation and end points to incorporate response patterns and biological correlates that better capture delayed, immune‑mediated tumour control. Details of specific revised criteria and correlative measures are presented conceptually; the full article contains expanded discussion accessible via subscription.
The fourth pillar positions OVs as a foundational immuno‑oncology platform using a triple‑A framework: admission, availability and activation of tumour‑specific T cells. The authors argue that payload‑engineered OVs uniquely satisfy all three prerequisites simultaneously: they admit tumour antigens into an immunogenic context, make those antigens available to antigen‑presenting cells, and activate the adaptive immune response through local adjuvancy and antigen presentation. In this framing, OVs are not merely local therapies with incidental systemic effects but systemic immune‑reprogramming platforms delivered locally.
The Perspective synthesizes early clinical data showing signals consistent with in situ vaccination and systemic immune activation. Reported observations include T cell clonotype broadening after intratumoural OV administration, abscopal regressions in non‑injected lesions, and survival benefits in ICI‑refractory patients in initial studies. Based on these findings, the authors advocate a strategic approach in which OV‑prime, ICI‑amplify combinations are used: OVs generate new, diverse TSTs and ICIs then amplify those responses by releasing adaptive checkpoints. Specific trial outcomes, numerical data and full methodological detail are contained in the subscription article and are not reproduced in the preview.
The article includes illustrative figures: one depicting oncolytic viruses for in situ vaccination and another showing the triple‑A gate model for productive antitumour immunity across therapeutic modalities. These schematics summarize the proposed mechanisms by which intratumoural OVs generate antigen exposure, adjuvant signals and downstream T cell priming, and how those processes map onto the admission, availability and activation gates required for effective antitumour immunity.
In summary, the authors propose that next‑generation, payload‑engineered oncolytic viruses should be developed and evaluated as systemic immuno‑reprogramming platforms administered locally. They recommend prioritizing intratumoural vaccination strategies, payload optimization for antigen presentation, revised clinical end points that capture immune kinetics, and clinical designs that combine OV priming with ICI amplification. The Perspective emphasizes conceptual and early clinical rationale but notes that detailed trial data and extended discussion are available in the full article, which requires subscription access.
References and further reading cited in the Perspective include historical landmark trials of checkpoint blockade and recent literature on immunotherapy and OV development; the preview lists multiple references but full reference context and in‑depth citations are available in the published article.